Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAPID-PROTECTION: an adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus

Next Previous
Trial Profile

RAPID-PROTECTION: an adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilgavimab/tixagevimab (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms RAPID-PROTECTION

Most Recent Events

  • 18 Jan 2023 According to ISRCTN: Current Controlled Trials record, recruitment started on 15 Nov 2022 and recruitment completion is expected on 30 April 2023
  • 18 Jan 2023 Planned End Date changed from 26 Jan 2024 to 26 Apr 2024.
  • 14 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top